RT Journal Article SR Electronic T1 Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.09.13.23295520 DO 10.1101/2023.09.13.23295520 A1 Clerc, Olivier F. A1 Datar, Yesh A1 Cuddy, Sarah AM A1 Bianchi, Giada A1 Taylor, Alexandra A1 Benz, Dominik C A1 Robertson, Matthew A1 Kijewski, Marie Foley A1 Jerosch-Herold, Michael A1 Kwong, Raymond Y A1 Ruberg, Frederick L A1 Liao, Ronglih A1 Di Carli, Marcelo F A1 Falk, Rodney H A1 Dorbala, Sharmila YR 2023 UL http://medrxiv.org/content/early/2023/09/15/2023.09.13.23295520.abstract AB Background Myocardial immunoglobulin light-chain (AL) amyloid deposits trigger heart failure, cardiomyocyte stretch and myocardial injury, leading to adverse cardiac outcomes. Positron emission tomography/computed tomography (PET/CT) with 18F-florbetapir, a novel amyloid-targeting radiotracer, can quantify left ventricular (LV) amyloid burden, but its prognostic value is not known. Therefore, we aimed to evaluate the prognostic value of LV amyloid burden quantified by 18F-florbetapir PET/CT and to identify mechanistic pathways mediating its association with outcomes.Methods Eighty-one participants with newly-diagnosed systemic AL amyloidosis were prospectively enrolled and underwent 18F-florbetapir PET/CT. LV amyloid burden was quantified using 18F-florbetapir LV percent injected dose (%ID). Mayo AL stage was determined using troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and difference between involved and uninvolved free light chain levels. Major adverse cardiac events (MACE) were defined as all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months.Results Among participants (median age 61 years, 57% males), 36% experienced MACE. Incidence of MACE increased across tertiles of LV amyloid burden from 7% to 63% (p<0.001). LV amyloid burden was significantly associated with MACE in univariable analysis (hazard ratio 1.45, 95% confidence interval 1.15-1.82, p=0.002). However, this association became non-significant in multivariable analyses adjusted for Mayo AL stage. Mediation analysis showed that the association between 18F-florbetapir LV %ID and MACE was primarily mediated by NT-proBNP (p<0.001), a marker of cardiomyocyte stretch and component of Mayo AL stage.Conclusion In this first study to link cardiac 18F-florbetapir uptake to subsequent outcomes, LV amyloid burden estimated by LV %ID predicted MACE in AL amyloidosis. But this effect was not independent of Mayo AL stage. LV amyloid burden was associated with MACE primarily via NT-pro-BNP, a marker of cardiomyocyte stretch and component of Mayo AL stage. These findings provide novel insights into the mechanism through which myocardial AL amyloid leads to MACE.Clinical Perspective In systemic light-chain (AL) amyloidosis, cardiac involvement is the key determinant of adverse outcomes. Usually, prognosis is based on the Mayo AL stage, determined by troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and the difference between involved and uninvolved immunoglobulin free light chain levels (dFLC). Cardiac amyloid burden is not considered in this staging. In the present study, we used the amyloid-specific radiotracer 18F-florbetapir to quantify left ventricular (LV) amyloid burden in 81 participants with newly-diagnosed AL amyloidosis and evaluated its prognostic value on major adverse outcomes (MACE: all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months). We found that higher LV amyloid burden by 18F-florbetapir positron emission tomography/computed tomography (PET/CT) was strongly associated with MACE. However, this association became non-significant after adjustment for the Mayo AL stage. Mediation analysis offered novel pathophysiological insights, implying that LV amyloid burden leads to MACE predominantly through cardiomyocyte stretch and light chain toxicity (by NT-proBNP), rather than through myocardial injury (by troponin T), also considering the severity of plasma cell dyscrasia (by dFLC). This mediation by NT-proBNP may explain why the association with outcomes was non-significant with adjustment for Mayo AL stage. Together, these results establish quantitative 18F-florbetapir PET/CT as a valid method to predict adverse outcomes in AL amyloidosis. These results support the use of 18F-florbetapir PET/CT to measure the effects of novel fibril-depleting therapies, in addition to plasma cell therapy, to improve outcomes in systemic AL amyloidosis.Competing Interest StatementClerc: Research fellowship from the International Society of Amyloidosis and Pfizer. Cuddy: Investigator-initiated research grant from Pfizer. Ruberg: Consulting fees from Astra Zeneca, research support from Pfizer, Alnylam, and Ionis/Akcea. DiCarli: Research grant from Gilead and Alnylam Pharmaceuticals, in-kind research support from Amgen, consulting fees from Sanofi, MedTrace Pharma, and Valo Health. Kwong: Grant funding from Alynlam Pharmaceuticals. Falk: Consulting fees from Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Caelum Biosciences, research funding from GlaxoSmithKline and Akcea. Dorbala: Consulting fees: Pfizer, GE Health Care, Astra Zeneca, Novo Nordisk; investigator-initiated grant: Pfizer, GE Healthcare, Attralus, Siemens, Philips. The other authors do not have any conflicts of interest to declare.Funding StatementThis work was supported by the National Institutes of Health. Dorbala: R01 HL 130563; K24 HL 157648; AHA16 CSA 2888 0004; AHA19SRG34950011 Falk: R01 HL 130563 Liao: AHA16 CSA 2888 0004; AHA19SRG34950011 Ruberg: R01 HL 130563; R01 HL 093148 https://clinicaltrials.gov/ct2/show/NCT02641145Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective study was approved by the Mass General Brigham Human Research Committee (NCT02641145).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this article cannot be shared publicly due to data privacy as defined in the informed consent document.